2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2789

Deficiency of the Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Induces Replication Stress in RA Fibroblast-like Synoviocytes (FLS) and Exacerbates Arthritis Severity
Abstract Number: 2790

Regulation of ASK1 Expression and Its Role in Rheumatoid Arthritis (RA)
Abstract Number: 2791

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis
Abstract Number: 2792

Th22 Cells Are a Potent Inducer of Osteoclastogenesis in Rheumatoid Arthritis
Abstract Number: 2793

Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)
Abstract Number: 2794

Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis
Abstract Number: 2795

Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study
Abstract Number: 2796

A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis
Abstract Number: 2797

Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
Abstract Number: 2798

A Randomized, Double-Blind Study Comparing PF-06438179/GP1111, a Potential Infliximab Biosimilar, and Infliximab, Both in Combination with MTX, As Treatment for Patients with Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Therapy
Abstract Number: 2799

Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)
Abstract Number: 2800

Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Abstract Number: 2801

Effects of Anti-IL17 Blockade with Secukinumab on Systemic and Local Immune Responses: A Mechanism-of-Action Study in Peripheral Spondyloarthritis
Abstract Number: 2802

Sustained Remission of Inflammation Is Associated with Reduced Structural Damage on SI Joint MRI in Patients with Early Axial Spa: Evidence to Support the Concept of Treat-to-Target
Abstract Number: 2803

Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].